USPTO Art Unit 1654 Prosecution Statistics

Art Unit Information

Art Unit: 1654
Group: 1650
Tech Center: 1600
Total Cases: 12,399
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19042887GIP/GLP1 AGONIST COMPOSITIONSJanuary 2025May 2025Allow400YesNo
18980129Compositions and Methods for Treating Endocrine Diseases and DisordersDecember 2024March 2025Allow310NoNo
18955504DESMOPRESSIN ORAL COMPOSITIONSNovember 2024May 2025Allow610YesNo
18949272FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASESNovember 2024June 2025Allow721NoNo
18905498KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPINOctober 2024April 2025Allow710NoNo
18829566CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRASSeptember 2024November 2024Allow200YesNo
18824970POLYPEPTIDE WITH ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITY, AND PREPARATION METHOD AND USE THEREOFSeptember 2024March 2025Allow611YesNo
18821027AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTAugust 2024May 2025Allow820NoNo
18818974METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSAugust 2024December 2024Allow310NoNo
18778554PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFJuly 2024December 2024Allow510YesNo
18773066CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTIONJuly 2024December 2024Allow501YesNo
18733576ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2024September 2024Allow310NoNo
18731133COMPOSITIONS AND METHOD FOR TREATING ACUTE RADIATION SYNDROMEMay 2024June 2025Allow1310NoNo
18674657POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOFMay 2024January 2025Allow811YesNo
18670946Methods and Compositions to Assist and Support the Formation of Red Blood Cells and HemoglobinMay 2024November 2024Allow610YesNo
18667958POLYPEPTIDE-COUPLED SMALL MOLECULE COMPOUND AND ANTIVIRAL APPLICATION THEREOFMay 2024December 2024Allow711YesNo
18640964AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTApril 2024May 2024Allow100YesNo
18640722IMMUNOREGULATORY MOLECULES AND USES THEREFORApril 2024June 2025Abandon1401NoNo
18634717METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSApril 2024August 2024Allow410YesNo
18625923DESMOPRESSIN ORAL COMPOSITIONSApril 2024October 2024Allow3811YesNo
18615150Compositions and Methods for Treating Endocrine Diseases and DisordersMarch 2024August 2024Allow501NoNo
18604400CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOFMarch 2024November 2024Allow811NoNo
18600557COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONSMarch 2024June 2025Allow1631YesNo
18598719IMMUNE CHECKPOINT INHIBITOR COMBINATIONSMarch 2024January 2025Allow1010NoNo
18595656METHODS OF TREATING OR PREVENTING STENT THROMBOSISMarch 2024May 2025Abandon1410NoNo
18444443COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOFFebruary 2024December 2024Allow1010NoNo
18439088FORMULATIONS FOR INTRAOCULAR DELIVERY OF PEPTIDES DERIVED FROM TYPE IV COLLAGENFebruary 2024May 2025Abandon1520YesNo
18436355SCAFFOLD PROTEINSFebruary 2024December 2024Allow1001NoNo
18431596FIBROIN-DERIVED PROTEIN COMPOSITIONFebruary 2024March 2025Allow1310NoNo
18422307METHODS FOR REGULATING FREE FATTY ACID FLUX USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSJanuary 2024April 2025Abandon1511NoNo
18419845SMALL PEPTIDE COMPOSITIONS AND USES THEREOFJanuary 2024June 2025Allow1701YesNo
18420397TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2AJanuary 2024May 2025Abandon1611NoNo
18420177Atomic Description of Immune Complex that Causes Heparin-Induced ThrombocytopeniaJanuary 2024December 2024Allow1110NoNo
18417206METHODS OF TREATING ALZHEIMERS DISEASEJanuary 2024March 2025Allow1410NoNo
18413260TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUGJanuary 2024April 2025Abandon1410NoNo
18412585NOVEL PTH MIMETIC PEPTIDE BASED ON PROTEIN DOMAIN RECONSTRUCTION AND APPLICATION THEREOFJanuary 2024May 2025Allow1610YesNo
18407324CNP PRODRUGS WITH LARGE CARRIER MOIETIESJanuary 2024March 2025Abandon1410NoNo
18402138BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSUREJanuary 2024November 2024Allow1110NoNo
18394401INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTSDecember 2023May 2025Allow1711NoNo
18392459STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAMEDecember 2023February 2025Allow1410NoNo
18537886SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOFDecember 2023February 2025Allow1411YesNo
18534620ATF5 Peptide Variants and Uses ThereofDecember 2023September 2024Allow1001NoNo
18528195POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSEDecember 2023May 2025Abandon1810NoNo
18527006ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASESDecember 2023April 2025Allow1611YesNo
18524472ANALOGUES OF PYYNovember 2023January 2025Allow1430YesNo
18522766METHODS OF MODULATING ALKNovember 2023January 2025Abandon1401NoNo
18520428ODORANT-BINDING PROTEIN COMPOSITIONS, METHODS AND USES THEREOFNovember 2023October 2024Allow1121YesNo
18518880COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo
18518879COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo
18514838MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOFNovember 2023April 2025Allow1721NoNo
18513575Method for Side Effect Reduction in the Use of Statins Via Physiologically Synthesized GlutathioneNovember 2023April 2025Abandon1621NoNo
18513146METHODS FOR TREATING CANCERNovember 2023January 2025Abandon1410NoNo
18511852ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAMENovember 2023September 2024Allow1010NoNo
18507346SWEET PROTEIN FROM TRUFFLENovember 2023July 2024Allow910NoNo
18505472WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAMENovember 2023December 2024Abandon1311NoNo
18504534COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIANovember 2023December 2024Allow1311NoNo
18386839SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACIDNovember 2023June 2025Allow1911YesNo
18497741CYSTINE KNOT SCAFFOLD PLATFORMOctober 2023January 2025Abandon1510NoNo
18497900PEPTIDE COMPOSITION AND RESPECTIVE USESOctober 2023April 2025Allow1821NoNo
18496636INJECTION PEN FOR SUBCUTANEOUS ADMINISTRATION OF A PEPTIDEOctober 2023March 2025Allow1721YesNo
18496150KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPINOctober 2023September 2024Allow1010YesNo
18496633USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENTOctober 2023September 2024Allow1010NoNo
18495932METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSOctober 2023March 2024Allow520NoNo
18491990INSECT NEUROPEPTIDES 2October 2023November 2024Allow1311YesNo
18491530METHODS AND COMPOSITIONS FOR TREATING CD44+ CANCERSOctober 2023July 2024Abandon901NoNo
18491099Reagents and methods for treating bacterial infectionOctober 2023November 2024Abandon1310NoNo
18486390COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASEOctober 2023March 2025Abandon1710NoNo
18484819LIQUID DALBAVANCIN COMPOSITIONSOctober 2023May 2024Allow711YesNo
18484451PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAMEOctober 2023December 2024Allow1420NoNo
18378229Charged Nutritive Proteins and MethodsOctober 2023June 2025Abandon2010NoNo
18482589VEGF TRAPS AND MINI-TRAPS AND METHODS FOR TREATING OCULAR DISORDERS AND CANCEROctober 2023March 2025Allow1811NoNo
18480170SYNTHETIC PEPTIDE COMPOUNDS AND METHODS OF USEOctober 2023January 2025Allow1511YesNo
18476587GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITISSeptember 2023December 2024Allow1410NoNo
18477490HEPCIDIN ANALOGUES AND USES THEREOFSeptember 2023December 2024Allow1410YesNo
18368347LONG-ACTING PARATHYROID HORMONESeptember 2023October 2024Allow1322YesNo
18464507HOOK FUSION PROTEIN FOR REGULATING THE CELLULAR TRAFFICKING OF A TARGET PROTEINSeptember 2023January 2025Allow1611YesNo
18464046PTH ProdrugsSeptember 2023September 2024Allow1210NoNo
18464024COMPOSITIONS AND METHODS OF USE FOR TREATMENT OR IMPROVEMENT OF THE CONDITION AND APPEARANCE OF SKINSeptember 2023August 2024Allow1210YesNo
18462983INJECTABLE PRESENTATIONS, SYRINGES AND COMPOSITIONS WITH SUSTAINED AND/OR CONTROLLED RELEASE OF LANREOTIDESeptember 2023September 2024Allow1210NoNo
18461812Methods and Compositions for Treating Vasomotor SymptomsSeptember 2023March 2025Abandon1811NoNo
18461912Treatment of Rhinosinusitis with P-glycoprotein InhibitorsSeptember 2023November 2024Allow1520NoNo
18460024SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATIONSeptember 2023March 2025Allow1820NoNo
18458076METHODS AND COMPOSITIONS FOR NUCLEIC ACID AND PROTEIN PAYLOAD DELIVERYAugust 2023October 2024Abandon1411NoNo
18454855ANTIMICROBIAL PEPTIDE SPAMPCIN56-86 FROM SCYLLA PARAMAMOSAIN AND APPLICATIONS THEREOFAugust 2023June 2024Allow910NoNo
18454319METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROMEAugust 2023February 2025Allow1820YesNo
18452724COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOFAugust 2023January 2025Allow1720YesNo
18452479PEPTIDIC DIAGNOSTIC COMPOSITIONSAugust 2023March 2025Allow1911YesNo
18451467GENERATING A MICROEMULSION FORMATION WITH IMPROVED SOLUBILITYAugust 2023May 2025Abandon2121YesNo
18451581TREATING A DISEASE USING A PHARMACEUTICALLY ACTIVE INGREDIENT PRESENT IN A PSEUDO-TERNARY PHASE SYSTEMAugust 2023May 2025Abandon2101NoNo
18451456FORMING A SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMAugust 2023August 2024Abandon1211NoNo
18450056INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDESAugust 2023August 2024Allow1210NoNo
18447049ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAMEAugust 2023July 2024Allow1110YesNo
18446712ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAMEAugust 2023July 2024Allow1210YesNo
18366653LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USEAugust 2023March 2025Allow1911YesNo
18365328LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOFAugust 2023March 2024Allow811YesNo
18365367LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOFAugust 2023March 2024Allow710NoNo
18364665IMMUNOMODULATORY PEPTIDEAugust 2023March 2025Allow1910NoNo
18363810THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUESAugust 2023August 2024Allow1300NoNo
18363178MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONSAugust 2023January 2025Allow1811YesNo
18363316METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANESAugust 2023January 2025Allow1811NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1654.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
85
Examiner Affirmed
56
(65.9%)
Examiner Reversed
29
(34.1%)
Reversal Percentile
58.0%
Higher than average

What This Means

With a 34.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
929
Allowed After Appeal Filing
231
(24.9%)
Not Allowed After Appeal Filing
698
(75.1%)
Filing Benefit Percentile
15.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1654 - Prosecution Statistics Summary

Executive Summary

Art Unit 1654 is part of Group 1650 in Technology Center 1600. This art unit has examined 12,399 patent applications in our dataset, with an overall allowance rate of 59.3%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1654's allowance rate of 59.3% places it in the 13% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1654 receive an average of 1.67 office actions before reaching final disposition (in the 36% percentile). The median prosecution time is 31 months (in the 36% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.